01 September 2021

2 minutes to read

Source / Disclosures

Disclosures: Brandt is an employee and may hold stock and / or stock options with Acadia Pharmaceuticals Inc. Please see the study for relevant financial information from all other authors.


We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

According to the results published in Clinical Gerontologist.

“There are no published studies that describe the symptoms, current treatment regimens and existing treatment needs of people with dementia-related psychosis (PRD) from a patient or care partner perspective. Such stories are needed to effectively identify and prioritize the treatment of the most powerful symptoms of dementia-related psychosis ”, Teresa Brandt, PhD, project director of clinical and regulatory affairs at Acadia Pharmaceuticals in California, and colleagues wrote. “This study aimed to fill this gap in the literature by characterizing the impact of psychosis symptoms, treatment needs, clinically important outcomes, and preferences for the benefits and risks of treatment in people with psychosis-related psychosis. Madness.”

In a prospective observational, non-interventional study, researchers received qualitative interview responses from 16 participants, one of whom had a DRP, and 15 care partners (mean age, 85.5 years; 66.7% d ‘men;). They received quantitative responses to the survey from 212 participants, of whom 26 had a DRP (mean age, 64.6 years; 57.7% male); 186 care partners (mean age 78.1 years; 48.9% men). All participants were from the United States, 18 years of age or older, and in written and spoken English. Care partners were defined by researchers as “people who provided at least 20 hours per week of direct in-person care to a person with PID.”

Therese Brandt

The qualitative part of the study consisted of a telephone interview between the researchers and 16 participants to determine the nature, frequency and severity of symptoms, in addition to the impact they have on the lives of individuals. Using the Hallucination and Delusions domains of the Positive Symptom Rating Scale, the researchers developed a one-hour interview, conducted between October 29, 2019 and December 13, 2019.

The quantitative component of the study required 212 participants who were not involved in the qualitative interviews to complete an online survey between November 14, 2019 and January 21, 2020. Participants answered 35 closed questions regarding background medical; the occurrence, severity, frequency and impact of symptoms; treatments taken; effectiveness of the treatments taken; and the desired therapeutic benefits.

The researchers recorded visual hallucinations (93.8%, qualitative group; 53.8% of those with DRP, 52.7% of care partners, quantitative group), auditory hallucinations (68.8% qualitative group; 30 % of those with DRP, 29% of care partners, quantitative group), delusions of persecution and distortion of the senses were the most common symptoms among participants. The most common were difficulty differentiating fact from fiction, increased anxiety, and effects on personal relationships.

When asked about treatment methods, participants said they were “less than moderately helpful,” with a median Visual Analog Scale (VAS) score of 2 out of 5 reported by those with DRP and care partners ( EVA range = 0 [“not well at all”] at 5 [“extremely well”]).

“The results provide insight into the most pressing therapeutic needs from a patient’s perspective by describing the nature, frequency and severity of symptoms and the specific impacts they have on the lives of individuals,” wrote Brandt et al. colleagues. “The symptoms caused people with PRD to question their understanding of reality and decreased their confidence in their ability to fully engage in daily life, and current treatment options were not providing adequate relief. symptoms. “

The clinical implications of this study included how current treatment options did not address the symptoms of DRP and that ideal therapy would improve symptoms so that individuals could defer the reality of psychotic experiences.

Limitations of the study included potential recall bias, limited inclusion, and limited diversity due to a majority of white participants.